Department of Respiratory Medicine, Stobhill Hospital, Glasgow, UK.
J Thorac Oncol. 2010 Jul;5(7):988-92. doi: 10.1097/JTO.0b013e3181da78f9.
Although only the minority of patients with non-small cell lung cancer (NSCLC) are suitable for surgical resection, it offers the best possibility of cure. The aim of this study was to examine the relationship between the clinicopathological status, the preoperative systemic inflammatory response, and survival in patients undergoing potentially curative resection for NSCLC.
Data from 96 patients who underwent resection of NSCLC between 2000 and 2003 were collected retrospectively and that for 2004-2006 prospectively.
All patients had Eastern cooperative oncology group performance status 0 or 1. No patient had T4, unresectable nodal or metastatic disease, and all macroscopic tumors were removed, with subsequent negative surgical margins. The majority of patients were older than 60 years (71%), men (57%), underwent a lobectomy (65%), and had tumor, node, metastasis stage I disease (66%). Of the markers of the systemic inflammatory response, white cell count, C-reactive protein, and albumin, only an elevated C-reactive protein (>10 mg/L) was associated with cancer-specific survival. On multivariate analysis, only tumor, node, metastasis stage (hazard ratio 1.88, 95% confidence interval 1.34-2.63, p < 0.001) and preoperative C-reactive protein (hazard ratio 1.67, 95% confidence interval 1.01-2.83, p < 0.05) retained independent significance. Those patients with a preoperative C-reactive protein concentration >10 mg/L had a median survival of 26.2 months compared with 75.9 months in those patients with a C-reactive protein < or =10 mg/L (p < 0.05).
The results of this study indicate that the presence of a systemic inflammatory response predicts poor outcome in patients who have undergone potentially curative resection for lung cancer.
尽管只有少数非小细胞肺癌(NSCLC)患者适合手术切除,但这是治愈的最佳机会。本研究旨在研究行潜在可治愈性切除的 NSCLC 患者的临床病理状态、术前全身炎症反应与生存之间的关系。
回顾性收集了 2000 年至 2003 年间接受 NSCLC 切除术的 96 例患者的数据,并前瞻性收集了 2004 年至 2006 年的数据。
所有患者的东部合作肿瘤组体能状态均为 0 或 1。没有患者有 T4、不可切除的淋巴结或转移疾病,所有肉眼肿瘤均被切除,随后切缘阴性。大多数患者年龄大于 60 岁(71%),男性(57%),行肺叶切除术(65%),且肿瘤、淋巴结、转移分期为 I 期(66%)。在全身炎症反应的标志物中,白细胞计数、C 反应蛋白和白蛋白中,只有升高的 C 反应蛋白(>10mg/L)与癌症特异性生存相关。多变量分析仅显示肿瘤、淋巴结、转移分期(危险比 1.88,95%置信区间 1.34-2.63,p<0.001)和术前 C 反应蛋白(危险比 1.67,95%置信区间 1.01-2.83,p<0.05)具有独立意义。术前 C 反应蛋白浓度>10mg/L 的患者中位生存时间为 26.2 个月,而 C 反应蛋白<或=10mg/L 的患者中位生存时间为 75.9 个月(p<0.05)。
本研究结果表明,全身炎症反应的存在预示着接受潜在可治愈性肺癌切除的患者预后不良。